Rubicon Research plans to raise ₹500 crore through a fresh issue for debt repayment and acquisitions, alongside an ₹877.5 crore offer for sale. The pharmaceutical company reported strong revenue and profit growth with margin expansion, boasting a higher RoNW than peers. However, high revenue concentration in the US and from top customers presents a risk.
​Rubicon Research plans to raise ₹500 crore through a fresh issue for debt repayment and acquisitions, alongside an ₹877.5 crore offer for sale. The pharmaceutical company reported strong revenue and profit growth with margin expansion, boasting a higher RoNW than peers. However, high revenue concentration in the US and from top customers presents a risk. by Soban News (international And National News)
